BiotechTube

Fresolimumab

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteogenesis Imperfecta

Conditions

Osteogenesis Imperfecta

Trial Timeline

Nov 15, 2017 → Jul 4, 2022

NCT ID
NCT03064074

About Fresolimumab

Fresolimumab is a phase 1 stage product being developed by Sanofi for Osteogenesis Imperfecta. The current trial status is completed. This product is registered under clinical trial identifier NCT03064074. Target conditions include Osteogenesis Imperfecta.

What happened to similar drugs?

1 of 7 similar drugs in Osteogenesis Imperfecta were approved

Approved (1) Terminated (2) Active (4)
✅Teriparatide (FORTEO) + PlacebosEli LillyApproved
🔄Zoledronic AcidNovartisPhase 3
🔄Romosozumab + BisphosphonateAmgenPhase 3
❌DenosumabAmgenPhase 3
❌Denosumab + Alternative osteoporosis medicationsAmgenPhase 3
🔄setrusumabUltragenyx PharmaceuticalPhase 3
🔄Bisphosphonate + SetrusumabUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03064074Phase 1Completed

Competing Products

16 competing products in Osteogenesis Imperfecta

See all competitors
ProductCompanyStageHype Score
Teriparatide (FORTEO) + PlacebosEli LillyApproved
43
Zoledronic AcidNovartisPhase 2
35
Zoledronic AcidNovartisPhase 2
35
Zoledronic AcidNovartisPhase 3
40
Romosozumab + BisphosphonateAmgenPhase 3
47
RomosozumabAmgenPhase 1
29
DenosumabAmgenPhase 3
32
Denosumab + Alternative osteoporosis medicationsAmgenPhase 3
32
SAR439459 + PlaceboSanofiPhase 1
21
BPS804Ultragenyx PharmaceuticalPhase 2
29
SetrusumabUltragenyx PharmaceuticalPhase 2/3
36
SetrusumabUltragenyx PharmaceuticalPhase 2
21
BPS804Ultragenyx PharmaceuticalPhase 2
21
setrusumabUltragenyx PharmaceuticalPhase 3
38
setrusumab + zoledronic acid (optional)Ultragenyx PharmaceuticalPhase 2
29
Bisphosphonate + SetrusumabUltragenyx PharmaceuticalPhase 3
38